AzTrials
AzTrials

Gait Disorders, NeurologicNCT03787199

Feasibility of the Overground Bodyweight Supporting Walking System Andago

A study testing Andago and Treadmill in people with Gait Disorders, Neurologic and Cerebral Palsy, run by University Children's Hospital, Zurich at 1 site in Switzerland.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The overall aim of this project is to investigate the clinical utility of the Andago System, a CE certified mobile bodyweight supporting walking robot, in children with neuromotor disorders. Clinical utility encompasses practicability, acceptability, appropriateness, and accessibility. Read more about this study

Who is it for?
Ages Up to 18 years
Conditions the study is for
Gait Disorders, Neurologic, Cerebral Palsy, Stroke
What is being tested?
Andago and Treadmill
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
20 participants
Where
1 siteSwitzerland
Study dates
28 May 2018to 21 Mar 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 18 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Neuromotor or orthopaedic disorders
  • taller than 135 cm
  • able to understand simple instructions
  • able to walk 10 meters with or without walking aid
  • maximal age of 18 years (a minimal age is not defined as according to the growth curve, children younger than 7-8 years cannot be included because of insufficient height)
  • given informed consent.

Who cannot join

  • not consolidated fractures or bone fragility of the lower extremities
  • skin lesions in the harness' area which cannot be protected
  • unstable hip, knee and/or ankle Joints
  • reduced head control or inability to maintain an upright Position
  • inability to communicate discomfort or pain
  • surgery in the last 3 months
Show all 12Show fewer
  • newly implanted baclofen-pump (or children highly sensitive to it)
  • implanted pacemakers
  • passive knee extension deficit > 30°
  • self-selected walking speed > 3.2 km/h.
  • weight > 135 kg
  • height > 2 m.

Trial locations and contacts

1 site in 1 country.

Switzerland1 site
  • Rehabilitation Center of the University Children's Hospital

    Affoltern am Albis, Canton of Zurich, 8910

Other trials in Switzerland

About this study

The overall aim of this project is to investigate the clinical utility of the Andago System, a CE certified mobile bodyweight supporting walking robot, in children with neuromotor disorders. Clinical utility encompasses practicability, acceptability, appropriateness, and accessibility. In this study, the investigators would like to investigate several aspects of clinical utility that belong to the first three components.

Read the detailed description

The specific aims of the current project are:

  1. To investigate the practicability, the investigators plan to determine the accuracy of the weight-supporting system of the Andago and the time needed for donning and doffing. The investigators also evaluate the number of times that the device stops and the nature of these stops (due to errors, sitting of the patient, when preventing falls, or when the patient moves too fast).
  2. To evaluate acceptability, the investigators plan to evaluate differences in motivation and measures reflecting safety (i.e. number of falls prevented) and subjective feeling of safety when patients walk with the Andago compared to walking with their usual walking aids.
  3. To evaluate the appropriateness, the investigators are interested in differences between walking on a treadmill and walking overground with this device or changes that occur during walking overground when changing the level of BWS through the unloading system. Therapists should be aware of these differences to know what the advantage of such a system could be or how adjustments in settings influence the walking pattern. The investigators plan two investigations: (a) To determine differences in stride-to-stride variability, leg muscle activation, hip, knee and ankle joint kinematics and other gait parameters during walking in the Andago (overground) versus walking on a treadmill. (b) To determine differences in the same parameters when walking in the Andago with different levels of BWS. These levels are the minimal required level of BWS to walk without buckling the knees (ref BWS), ref BWS plus 15% and ref BWS plus 30%.

To investigate these aims, the patients will be asked to participate in 3 appointments, which should be scheduled within 10 days.

Being tested
Andago, Treadmill
Keywords
Andago, Feasibility, Pediatric Neurorehabilitation
Medical subject headings
Gait Disorders, Neurologic, Cerebral Palsy, Stroke, Brain Injuries, Traumatic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AndagoDevice

    The Andago is a body-weight supporting device with which a patient can walk overground

  • TreadmillOther

    Bodyweight supported treadmill walking

Study groups in NCT03787199
Study groupRoleWhat they receive
AndagoExperimentalApplication of walking over-ground with body-weight support in the Andago
Receives: Device: Andago
TreadmillActive comparatorApplication of walking on a treadmill with body-weight support
Receives: Other: Treadmill

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Stride to stride variability

    Variability in stride length recorded during at least 20 steps for each of the following conditions: Andago with reference bodyweight support; Andago with 15% more bodyweight support; Andago with 30% more bodyweight support; and treadmill condition with reference bodyweight support

    Measured: Appointment 3 (between minute 25 and minute 55 )

Secondary outcomes (2)
  1. Leg muscle activity

    Amplitude of electromyographic recordings recorded during at least 20 steps for each of the following conditions: Andago with reference bodyweight support; Andago with 15% more bodyweight support; Andago with 30% more bodyweight support; and treadmill condition with reference bodyweight support

    Measured: Appointment 3 (between minute 25 and minute 55 )

  2. Leg joint angles

    Joint angles recorded with electrogoniometers during at least 20 steps for each of the following conditions: Andago with reference bodyweight support; Andago with 15% more bodyweight support; Andago with 30% more bodyweight support; and treadmill condition with reference bodyweight support

    Measured: Appointment 3 (between minute 25 and minute 55)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Dec 2018
  2. Study start28 May 2018
  3. Primary completion19 Mar 2019
  4. Study completion21 Mar 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Device feasibility
Allocation
Non-randomised
Intervention model
Single group
Model description
Feasibility study, including a comparison between Andago and treadmill walking conditions (as we include a heterogeneous group of participants concerning age (children/adolescents), diagnosis, walking ability, etc., we include in this feasibility study 20 participants - rather than the usual 10). Patients participate in 3 appointments (planned within 10 days): Appointment 1 (60 min): patient characteristics, clinical tests (Selective Control Assessment of the Lower Extremity / Manual Muscle Testing / 10 meter walk test or 10MWT); practising on treadmill and in Andago; questions to participants Appointment 2 (45 min): determine accuracy of the unloading system; practicing on treadmill and in Andago; questions to participant Appointment 3 (60-90 min): 10MWT at onset and end; measurement of stride length, leg muscle EMG and joint kinematics during walking on treadmill with bodyweight unloading and walking overground with Andago with 3 levels of bodyweight unloading
Masking
None (open label)
Enrolment
20 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03787199
Sponsor's protocol ID
2018-00412
Other IDs
2018
Status last verified
Apr 2019
First submitted
23 Apr 2018
Last updated
18 Apr 2019
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided: We have to check with the local ethics committee whether our pseudonymized data can be shared

Publications

  • van Hedel HJA, Rosselli I, Baumgartner-Ricklin S. Clinical utility of the over-ground bodyweight-supporting walking system Andago in children and youths with gait impairments. J Neuroeng Rehabil. 2021 Feb 8;18(1):29. doi: 10.1186/s12984-021-00827-1.

    PubMed 33557834

Questions about this trial

What is this clinical trial studying?

A study testing Andago and Treadmill in people with Gait Disorders, Neurologic and Cerebral Palsy, run by University Children's Hospital, Zurich at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Apr 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Stride to stride variability (time frame: Appointment 3 (between minute 25 and minute 55 )). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03787199, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Apr 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in